Clinical Trial

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-27.
Status change: Not Yet Recruiting → Recruiting 2025-05-13
Trial Details
NCT Number NCT06853444
Lead Sponsor Shanghai Escugen Biotechnology Co., Ltd
Conditions Immune Thrombocytopenia (ITP)
Enrollment 84 participants
Start Date 2025-05-08
Primary Completion 2026-03-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-16